アフターアワーズ： 1.27 -0.04 -3.05%

Ocuphire Pharma Inc (OCUP)

Ocuphire Pharma Inc (OCUP) 最新ニュース

Ocuphire Pharma Inc (OCUP)

Ocuphire Pharma Inc (OCUP) 最新ニュース

Ocuphire Pharma releases results from MIRA-2 and MIRA-3 clinical trials for phentolamine ophthalmic solution 0.75% for pharmacologically-induced mydriasis - Ophthalmology Times

Ocuphire reports positive phase 3 results for eye treatment RYZUMVI By Investing.com - Investing.com UK

Ocuphire Pharma Announces Publication of Full Phase 3 - GlobeNewswire

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology - StockTitan

OFS Credit Company, Inc. Prices Preferred Stock Offering - Business Wire

Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch

OFS Credit to offer preferred stock in public offering - MSN

Ratio Review: Analyzing Ocugen Inc (OCGN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Analyzing SOPHiA GENETICS (NASDAQ:SOPH) & Cyclo Therapeutics (NASDAQ:CYTH) - Defense World

Oaktree Specialty Lending director buys shares worth over $16,000 By Investing.com - Investing.com Canada

Is OCGN’s price to cash per share ratio a concern for investors? - US Post News

Option Care Health, Inc. (NASDAQ:OPCH) Position Increased by First Eagle Investment Management LLC - Defense World

Option Care Health, Inc. (NASDAQ:OPCH) Shares Sold by DekaBank Deutsche Girozentrale - Defense World

Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal

Opaleye Management Inc. Increases Stake in Codexis Inc. - Yahoo Finance

All the Doctor Odyssey guest stars we know so far - Hidden Remote

Mydriasis Treatment Market Booming Worldwide With Leading Key - openPR

Full approval of PBC therapy Ocaliva rejected by FDA committee in 10-1 vote - Liver Disease News

American Century Companies Inc. Raises Position in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World

Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS - PMLiVE

Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates - MSN

Ocuphire Pharma commences phase 3 trial for presbyopia treatment - Investing.com India

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia - Yahoo Finance UK

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial - GlobeNewswire

Ocuphire Pharma commences phase 3 trial for presbyopia treatment - Investing.com

Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia - StockTitan

Ocuphire Pharma Inc [OCUP] Chief Scientific & Dev. Ofc. makes an insider purchase of 3,500 shares worth 6178.0. - Knox Daily

OCUP stock touches 52-week low at $1.15 amid market challenges - Investing.com

OCUP stock touches 52-week low at $1.15 amid market challenges - Investing.com India

OCUP stock touches 52-week low at $1.15 amid market challenges - Investing.com Canada

Analysts review Ocuphire Pharma Inc’s rating - Knox Daily

There is no way Ocuphire Pharma Inc (OCUP) can keep these numbers up - SETE News

Ocuphire Pharma Inc (OCUP) stock: A year of ups and downs - US Post News

Ocuphire Pharma (NASDAQ:OCUP) Stock Quotes, Forecast and News Summary - Benzinga

Ocuphire Pharma Inc’s latest rating changes from various analysts - Knox Daily

Vanguard Group Inc. Purchases 64,400 Shares of Ocuphire Pharma, Inc. (NASDAQ:OCUP) - Defense World

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher - Simply Wall St

Ocuphire Pharma Announces 2024 Second Quarter Financial Results - Vision Monday

Ocuphire Pharma (STU:R3X1) EPS (Basic) : €-0.50 (TTM As of Jun. 2024) - GuruFocus.com

Ocuphire Pharma (STU:R3X1) EV-to-Revenue : -0.39 (As of Aug. 18, 2024) - GuruFocus.com

OCUP (Ocuphire Pharma) 3-Year FCF Growth Rate : 67.10% (As of Jun. 2024) - GuruFocus.com

OCUP (Ocuphire Pharma) Debt-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com

OCUP (Ocuphire Pharma) 50-Day SMA : $1.71 (As of Aug. 17, 2024) - GuruFocus.com

OCUP (Ocuphire Pharma) Net Income : $-14.11 Mil (TTM As of Jun. 2024) - GuruFocus.com

Canaccord Genuity Group Reaffirms Buy Rating for Ocuphire Pharma (NASDAQ:OCUP) - Defense World

Ocuphire Pharma (FRA:R3X1) PE Ratio (TTM) : At Loss (As of Aug. 18, 2024) - GuruFocus.com

Was anything negative for Ocuphire Pharma Inc (OCUP) stock last session? - US Post News

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasted to Post Q3 2024 Earnings of ($0.30) Per Share - Defense World

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance

Ocuphire shares price target cut, buy rating held on FDA approval milestone - Investing.com Canada

Ocuphire Pharma Inc (OCUP) Stock: A Year of Declines and Increases - The InvestChronicle

Ocuphire shares price target cut, buy rating held on FDA approval milestone - Investing.com

Financial Health Check: Examining Ocuphire Pharma Inc (OCUP)’s Key Ratios - The Dwinnex

OCUP stock touches 52-week low at $1.47 amid market challenges - Investing.com

OCUP stock touches 52-week low at $1.47 amid market challenges - Investing.com Canada

OCUP stock touches 52-week low at $1.47 amid market challenges - Investing.com India

OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace

Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update - GlobeNewswire

Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance UK

Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update - StockTitan

Virtu Financial LLC Takes $36,000 Position in Ocuphire Pharma, Inc. (NASDAQ:OCUP) - Defense World

Ocuphire Pharma to Present at Two Investor Conferences in August - GlobeNewswire

Ocuphire Pharma to Present at Two Investor Conferences in August - StockTitan

Here's Why We're Not At All Concerned With Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation - Yahoo Finance

OCUPに似た銘柄